Silexion Therapeutics Approves 1-for-24 Reverse Stock Split to Maintain Nasdaq Listing

Filing content

The company received shareholder approval for a 1-for-24 reverse stock split to meet Nasdaq listing requirements and reported restoring its shareholders' equity above the minimum threshold as of September 30, 2026.